TITLE

Hepatitis C Viremia Persistently Suppressed by HAART

PUB. DATE
April 2003
SOURCE
Clinical Infectious Diseases;4/15/2003, Vol. 36 Issue 8, p1086
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
20507802

 

Related Articles

  • Clinical Impact of GB Virus C Viremia on Patients with HIV Type 1 Infection in the Era of Highly Active Antiretroviral Therapy. Wang-Huei Sheng; Chien-Ching Hung; Ruei-Jiuan Wu; Jann-Tay Wang; Pei-Jer Chen; Shan-Chwen Chang; Jia-Horng Kao // Clinical Infectious Diseases;2/15/2007, Vol. 44 Issue 4, p584 

    Background. The influence of GB virus C (GBV-C) viremia on clinical outcomes of patients with human immunodeficiency virus type 1 (HIV-1) infection remains controversial in the era of highly active antiretroviral therapy (HAART). Methods. A prospective observational study was conducted to...

  • Clearance of Hepatitis G viremia in a Human Immunodeficiency Virus--Positive Patient by... Toyoda, Hidenori; Fukuda, Yoshihide; Takamatsu, Junki // Clinical Infectious Diseases;11/1/1999, Vol. 29 Issue 5, p1332 

    Discusses the clearance of hepatitis G viremia in a human immunodeficiency virus (HIV)-positive patient by high-activity antiretroviral therapy (HAART). Diagnosis for a 40-year-old HIV-positive man; Protease inhibitor therapy for the patient; Association of coinfection with HIV with persistent...

  • HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Buzón, Maria J.; Massanella, Marta; Llibre, Josep M.; Esteve, Anna; Dahl, Viktor; Puertas, Maria C.; Gatell, Josep M.; Domingo, Pere; Paredes, Roger; Sharkey, Mark; Palmer, Sarah; Stevenson, Mario; Clotet, Bonaventura; Blanco, Julià; Martinez-Picado, Javier // Nature Medicine;Apr2010, Vol. 16 Issue 4, p460 

    Highly active antiretroviral therapy (HAART) results in potent and durable suppression of HIV-1 viremia. However, HIV-1 replication resumes if therapy is interrupted. Although it is generally believed that active replication has been halted in individuals on HAART, immune activation and...

  • Correspondence.  // Clinical Infectious Diseases;4/15/2003, Vol. 36 Issue 8, p1086 

    Presents comments about issues concerning infectious diseases. View of hematospermia as a presenting symptom of schistosomiasis; Suppression of hepatitis C viremia by highly active antiretroviral therapy; Safety of voriconazole and dose individualization.

  • Patterns and Causes of Suboptimal Response to Tenofovir-Based Therapy in Individuals Coinfected With HIV and Hepatitis B Virus. Matthews, Gail V.; Seaberg, Eric C.; Avihingsanon, Anchalee; Bowden, Scott; Dore, Gregory J.; Lewin, Sharon R.; Sasadeusz, Joe; Revill, Peter A.; Littlejohn, Margaret; Hoy, Jennifer F.; Finlayson, Robert; Ruxrungtham, Kiat; Saulynas, Melissa; Locarnini, Stephen; Thio, Chloe L. // Clinical Infectious Diseases;May2013, Vol. 56 Issue 9, pe87 

    In this international prospective cohort of 165 individuals coinfected with HIV and hepatitis B virus (HBV), 3 patterns of suboptimal response to tenofovir therapy were identified: persistent viremia, viral rebound, and viral blips. Suboptimal adherence was associated with detectable HBV DNA,...

  • Residual Viremia in an RT-SHIV Rhesus Macaque HAART Model Marked by the Presence of a Predominant Plasma Clone and a Lack of Viral Evolution. Kauffman, Robert C.; Villalobos, Andradi; Bowen, Joanne H.; Adamson, Lourdes; Schinazi, Raymond F. // PLoS ONE;Feb2014, Vol. 9 Issue 2, p1 

    Highly active antiretroviral therapy (HAART) significantly reduces HIV-1 replication and prevents progression to AIDS. However, residual low-level viremia (LLV) persists and long-lived viral reservoirs are maintained in anatomical sites. These reservoirs permit a recrudescence of viremia upon...

  • Case Report: Hepatitis C Virus Activation in HIV-Infected Patients Initiating Highly Active Antiretroviral Therapy. Kim, H. Nina; Harrington, Robert D.; Shuhart, Margaret C.; Cook, Linda; Morishima, Chihiro; Jerome, Keith R.; Wang, Chia C. // AIDS Patient Care & STDs;Oct2007, Vol. 21 Issue 10, p718 

    We describe repeated episodes of hepatitis C (HCV) activation associated with initiation of highly active antiretroviral therapy (HAART) in two HIV/HCV coinfected individuals with undetectable serum HCV RNA. Both patients developed high HCV viremia (>1 million IU/mL) and elevations in...

  • Impaired Recovery of CD4+ Cell Counts Following Highly Active Antiretroviral Therapy in Drug-Naïve Patients Coinfected with Human Immunodeficiency Virus and Hepatitis C Virus. Macías, J.; Pineda, J. A.; Lozano, F.; Corzo, J. E.; Ramos, A.; León, E.; García-García, J. A.; Fernández-Rivera, J.; Mira, J. A.; Gómez-Mateos, J. // European Journal of Clinical Microbiology & Infectious Diseases;Nov2003, Vol. 22 Issue 11, p675 

    Coinfection with the human immunodeficiency virus (HIV) and the hepatitis C virus (HCV) is highly prevalent in southern Europe. However, there are few and contradictory data about the effect of HCV carriage on the response to highly active antiretroviral therapy (HAART). In this study, the...

  • Longitudinal changes in HIV-specific IFN-γ secretion in subjects who received Remune vaccination prior to treatment interruption. Huang, Kenneth H.; Boisvert, Marie-Pierre; Chung, Famane; Loignon, Maude; Zarowny, Don; Cyr, Lise; Toma, Emil; Bernard, Nicole F. // Journal of Immune Based Therapies & Vaccines;2006, Vol. 4, p7 

    Background: Despite the benefits of highly active antitretroviral therapy (HAART) for suppressing viral replication in HIV infection, virus persists and rebounds during treatment interruption (TI). This study explored whether HAART intensification with Remuneâ„¢ vaccination before TI can...

  • New globally faces of hepatitis B and C in the world. Alavian, Seyed-Moayed // Gastroenterology & Hepatology from Bed to Bench;Oct2011, Vol. 4 Issue 4, p171 

    The author reflects on the various aspects of hepatitis B virus (HBV) and hepatitis C virus (HCV). He mentions that HBV and HCV infections become major causes of cirrhosis, hepatocellular carcinoma (HCC), and chronic hepatitis. The author cites the goals of hepatitis therapy including sustained...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics